CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Immuneering reports preclinical support for atebimetinib combinations in pancreatic cancer

By Public Technologies
  • Immuneering will present new preclinical atebimetinib combination data at the EORTC-NCI-AACR symposium, scheduled for November 17-19, 2026.
  • Pancreatic cancer findings support combinations with targeted therapies; results will feature in a November 19 poster spotlight.
  • Anaplastic thyroid cancer findings support combining atebimetinib with chemotherapy; presentation is scheduled for November 18.
  • Phase 2 results presented at ASCO in June showed promising survival outcomes with atebimetinib plus chemotherapy in first-line pancreatic cancer.
  • Atebimetinib is currently being evaluated in the Phase 3 MAPKeeper 301 trial in first-line pancreatic cancer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneering Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611040730PRIMZONEFULLFEED9869952) on November 04, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk